Ebola vaccine trials: progress in vaccine safety and immunogenicity

References

• World Health Organization (WHO). Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56(2):271–293. PubMed PMID: 307456; PubMed Central PMCID: PMC2395567. eng.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Ebola haemorrhagic fever in Sudan, 1976. Bull World Health Organ. 1978;56(2):247–270. PubMed PMID: 307455; PubMed Central PMCID: PMC2395561. eng.
   PubMed Web of Science ®Google Scholar
• Emanuel J, Marzi A, Feldmann H. Filoviruses: ecology, molecular biology, and evolution. Adv Virus Res. 2018;100:189–221. PubMed PMID: 29551136; eng.
   PubMed Web of Science ®Google Scholar
• Bell BP, Damon IK, Jernigan DB, et al. Overview, control strategies, and lessons learned in the CDC response to the 2014–2016 ebola epidemic. MMWR Suppl. 2016 Jul 8;65(3):4–11. PubMed PMID: 27389903; eng.
   PubMedGoogle Scholar
• Mari Saez A, Weiss S, Nowak K, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med. 2015 Jan;7(1):17–23. PubMed PMID: 25550396; PubMed Central PMCID: PMCPMC4309665. eng.
   PubMed Web of Science ®Google Scholar
• Baseler L, Chertow DS, Johnson KM, et al. The pathogenesis of ebola virus disease. Annu Rev Pathol. 2017 Jan 24;12:387–418. PubMed PMID: 27959626; eng.
   PubMed Web of Science ®Google Scholar
• Urbanowicz RA, McClure CP, Sakuntabhai A, et al. Human adaptation of ebola virus during the West African outbreak. Cell. 2016 Nov 3;167(4):1079–1087.e5. PubMed PMID: 27814505; PubMed Central PMCID: PMCPMC5101188. eng.
   PubMed Web of Science ®Google Scholar
• Rougeron V, Feldmann H, Grard G, et al. Ebola and Marburg haemorrhagic fever. J Clin Virol. 2015 Mar;64:111–119. PubMed PMID: 25660265; eng.
   PubMed Web of Science ®Google Scholar
• Feldmann H, Sanchez A, Geisbert TW. Filoviridae: marburg and ebola viruses. Fields virology: sixth Edition. Philadelphia: Lippincott Williams Wilkins; 2013. p. 923–956.
   Google Scholar
• Coltart CE, Lindsey B, Ghinai I, et al. The Ebola outbreak, 2013–2016: old lessons for new epidemics. Philos Trans R Soc Lond B Biol Sci. 2017 May 26;372:1721. PubMed PMID: 28396469; PubMed Central PMCID: PMCPMC5394636. eng.
   Web of Science ®Google Scholar
• WHO. Ebola virus disease democratic Republic of the Congo; 2019 December 4. External Situation Report 70.
   Google Scholar
• WHO. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. Ebola Ring Vaccination Results. 2019 April 12.
   Google Scholar
• WHO. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response; 2019.
   Google Scholar
• Williamson ED, Westlake GE. Vaccines for emerging pathogens: prospects for licensure. Clin Exp Immunol. 2019 Apr 11. PubMed PMID: 30972733; eng. DOI:10.1111/cei.13284
   Web of Science ®Google Scholar
• Step 3: clinical research: U.S. Food and Drug Administration; 2019. [cited 2019 Sep]. Available from: https://www.fda.gov/patients/drug-development-process/step-3-clinical-research#phases
   Google Scholar
• US Department of Health and Human Services FaDA, Center for Biologics Evaluation and Research. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventative vaccine clinical trials. Rockville, MD: FDA 2007.
   Google Scholar
• National Institute of Allergy and Infectious Diseases NIoH. Division of Microbiology and Infectious Diseases (DMID) adult toxicity table; 2007.
   Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78(10):5458–5465. PubMed PMID: 15113924; eng.
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005 Jul;11(7):786–790. PubMed PMID: 15937495; eng.
   PubMed Web of Science ®Google Scholar
• Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007 Jan;3(1):e2. PubMed PMID: 17238284; PubMed Central PMCID: PMCPMC1779298. eng.
   PubMed Web of Science ®Google Scholar
• Feldmann H, Feldmann F, Marzi A. Ebola: lessons on Vaccine Development. Annu Rev Microbiol. 2018 Sep 8;72:423–446.
   PubMed Web of Science ®Google Scholar
• Kennedy SB, Bolay F, Kieh M, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017 Oct 12;377(15):1438–1447. PubMed PMID: 29020589; PubMed Central PMCID: PMCPMC5705229. eng.
   PubMed Web of Science ®Google Scholar
• Coller BG, Blue J, Das R, et al. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017 Aug 16;35(35 Pt A):4465–4469. PubMed PMID: 28647166; eng.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017 Feb 4;389(10068):505–518. PubMed PMID: 28017403; PubMed Central PMCID: PMCPMC5364328.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015 Aug 29;386(9996):857–866. PubMed PMID: 26248676.
   PubMed Web of Science ®Google Scholar
• Gsell PS, Camacho A, Kucharski AJ, et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis. 2017 Dec;17(12):1276–1284. PubMed PMID: 29033032; PubMed Central PMCID: PMCPMC5700805. eng.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Arribas JR, Rupp R, et al. Six-month safety data of recombinant vesicular stomatitis virus-zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis. 2017 Jun 15;215(12):1789–1798. PubMed PMID: 28549145; PubMed Central PMCID: PMCPMC5853326.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006 Jun;3(6):e177. PubMed PMID: 16683867; PubMed Central PMCID: PMCPMC1459482. eng.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010 Dec 16;29(2):304–313. PubMed PMID: 21034824; eng.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015 Jun 6;385(9984):2272–2279. PubMed PMID: 25817373; eng.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Wurie AH, Hou LH, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017 Feb 11;389(10069):621–628. PubMed PMID: 28017399; eng.
   PubMed Web of Science ®Google Scholar
• Dolzhikova IV, Zubkova OV, Tukhvatulin AI, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother. 2017 Mar 4;13(3):613–620. PubMed PMID: 28152326; PubMed Central PMCID: PMCPMC5360131. eng.
   PubMed Web of Science ®Google Scholar
• Quinn KM, Da Costa A, Yamamoto A, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol. 2013 Mar 15;190(6):2720–2735. PubMed PMID: 23390298; PubMed Central PMCID: PMCPMC3594325. eng.
   PubMed Web of Science ®Google Scholar
• Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014 Oct;20(10):1126–1129. PubMed PMID: 25194571; eng.
   PubMed Web of Science ®Google Scholar
• Ewer K, Rampling T, Venkatraman N, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med. 2016 Apr 28;374(17):1635–1646. PubMed PMID: 25629663; PubMed Central PMCID: PMCPMC5798586. eng.
   PubMed Web of Science ®Google Scholar
• Venkatraman N, Ndiaye BP, Bowyer G, et al. Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen - ChAd3-EBO-Z followed by MVA-EBO-Z in healthy adults in the UK and Senegal. J Infect Dis. 2018 Nov 8 PubMed PMID: 30407513; eng. DOI:10.1093/infdis/jiy639.
   Web of Science ®Google Scholar
• Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016 Jan;16(1):31–42. PubMed PMID: 26546548; PubMed Central PMCID: PMCPMC4700389. eng.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against Ebolavirus challenge. J Virol. 2011;85:4222–4233.
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006 Nov;13(11):1267–1277. PubMed PMID: 16988008; PubMed Central PMCID: PMCPMC1656552. eng.
   PubMed Web of Science ®Google Scholar
• Grant-Klein RJ, Altamura LA, Badger CV, et al. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccin Immunother. 2015;11(8):1991–2004. PubMed PMID: 25996997; eng.
   PubMed Web of Science ®Google Scholar
• Patel A, Reuschel EL, Kraynyak KA, et al. Protective efficacy and long-term immunogenicity in cynomolgus macaques by Ebola virus glycoprotein synthetic DNA vaccines. J Infect Dis. 2019 Jan 29;219(4):544–555. PubMed PMID: 30304515; eng.
   PubMed Web of Science ®Google Scholar
• Cashman KA, Wilkinson ER, Wollen SE, et al. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs. Hum Vaccin Immunother. 2017 Dec 2;13(12):3010–3019. PubMed PMID: 29135337; PubMed Central PMCID: PMCPMC5718824. eng.
   PubMed Web of Science ®Google Scholar
• Kibuuka H, Berkowitz NM, Millard M, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet. 2015 Apr 18;385(9977):1545–1554. PubMed PMID: 25540891; eng.
   PubMed Web of Science ®Google Scholar
• Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015 Feb 15;211(4):549–557. PubMed PMID: 25225676; PubMed Central PMCID: PMCPMC4318920. eng.
   PubMed Web of Science ®Google Scholar
• Tebas P, Kraynyak KA, Patel A, et al. Intradermal synCon(R) Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers. J Infect Dis. 2019 Mar 19. PubMed PMID: 30891607; eng. doi:10.1093/infdis/jiz132.
   PubMedGoogle Scholar
• Khurana S, Fuentes S, Coyle EM, et al. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat Med. 2016 Dec;22(12):1439–1447. PubMed PMID: 27798615; eng.
   PubMed Web of Science ®Google Scholar
• Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017 Jan 26;376(4):330–341. PubMed PMID: 25830322; PubMed Central PMCID: PMCPMC5408576. eng.
   PubMed Web of Science ®Google Scholar
• ElSherif MS, Brown C, MacKinnon-Cameron D, et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017 Jun 19;189(24):E819–E827. PubMed PMID: 28630358; PubMed Central PMCID: PMCPMC5478408.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016 Apr 28;374(17):1647–1660. PubMed PMID: 25830326; PubMed Central PMCID: PMCPMC5490784. eng.
   PubMed Web of Science ®Google Scholar
• Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015 Oct;15(10):1156–1166. PubMed PMID: 26248510; eng.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Fernandes JF, Bache EB, et al. Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: A phase I randomised trial. PLoS Med. 2017 Oct;14(10):e1002402. PubMed PMID: 28985239; PubMed Central PMCID: PMCPMC5630143. eng.
   PubMed Web of Science ®Google Scholar
• Heppner DG Jr., Kemp TL, Martin BK, et al. Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 Aug;17(8):854–866. PubMed PMID: 28606591.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008 Dec 9;26(52):6894–6900. PubMed PMID: 18930776; PubMed Central PMCID: PMC3398796. eng.
   PubMed Web of Science ®Google Scholar
• Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med. 2012 Oct 31;4(158):158ra146. PubMed PMID: 23115355; PubMed Central PMCID: PMCPMC3789651. eng.
   PubMed Web of Science ®Google Scholar
• Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110:1893–1898.
   PubMed Web of Science ®Google Scholar
• Dahlke C, Kasonta R, Lunemann S, et al. Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV Immunization. EBioMedicine. 2017 May;19:107–118. PubMed PMID: 28434944; PubMed Central PMCID: PMCPMC5440606. eng.
   PubMed Web of Science ®Google Scholar
• Poetsch JH, Dahlke C, Zinser ME, et al. Detectable vesicular stomatitis virus (VSV)-specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans. J Infect Dis. 2019 Jan 29;219(4):556–561. PubMed PMID: 30452666; PubMed Central PMCID: PMCPMC6350948. eng.
   PubMed Web of Science ®Google Scholar
• Li JX, Hou LH, Meng FY, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017 Mar;5(3):e324–e334. PubMed PMID: 28017642; eng.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhang Z, Gao H, et al. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum Vaccin Immunother. 2017 Sep 2;13(9):2078–2085. PubMed PMID: 28708962; PubMed Central PMCID: PMCPMC5612469. eng.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine. N Engl J Med. 2017 Mar 9;376(10):928–938. PubMed PMID: 25426834; eng.
   PubMed Web of Science ®Google Scholar
• De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016 Mar;16(3):311–320. PubMed PMID: 26725450; eng.
   PubMed Web of Science ®Google Scholar
• Lambe T, Rampling T, Samuel D, et al. Detection of vaccine-induced antibodies to Ebola virus in oral fluid. Open Forum Infect Dis. 2016 Jan;3(1):ofw031. PubMed PMID: 27004234; PubMed Central PMCID: PMCPMC4796941. eng.
   PubMed Web of Science ®Google Scholar
• Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA. 2016 Apr 19;315(15):1610–1623. PubMed PMID: 27092831; eng.
   PubMed Web of Science ®Google Scholar
• Mutua G, Anzala O, Luhn K, et al. Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya. J Infect Dis. 2019 Feb 23 PubMed PMID: 30796816; eng. DOI:10.1093/infdis/jiz071.
   Web of Science ®Google Scholar
• Anywaine Z, Whitworth H, Kaleebu P, et al. Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania. J Infect Dis. 2019 Feb 23 PubMed PMID: 30796818; eng. DOI:10.1093/infdis/jiz070.
   PubMed Web of Science ®Google Scholar
• Winslow RL, Milligan ID, Voysey M, et al. Immune responses to novel adenovirus type 26 and modified vaccinia virus ankara-vectored Ebola vaccines at 1 year. JAMA. 2017 Mar 14;317(10):1075–1077. PubMed PMID: 28291882; eng.
   PubMed Web of Science ®Google Scholar